menu
    • menu
    [{"orgOrder":0,"company":"Sanwa Kagaku Kenkyusho","sponsor":"Kissei Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Upacicalcet Sodium","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Sanwa Kagaku Kenkyusho","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanwa Kagaku Kenkyusho \/ Kissei Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Sanwa Kagaku Kenkyusho \/ Kissei Pharmaceutical"},{"orgOrder":0,"company":"Sanwa Kagaku Kenkyusho","sponsor":"Crinetics Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Paltusotine","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Sanwa Kagaku Kenkyusho","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sanwa Kagaku Kenkyusho \/ Sanwa Kagaku Kenkyusho","highestDevelopmentStatusID":"10","companyTruncated":"Sanwa Kagaku Kenkyusho \/ Sanwa Kagaku Kenkyusho"}]

    Find Clinical Drug Pipeline Developments & Deals by Sanwa Kagaku Kenkyusho

    Menu

    Sanwa Kagaku Kenkyusho

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sanwa Kagaku Kenkyusho

                            Japan arrow
                            ELCC
                            Not Confirmed

                            Sanwa Kagaku Kenkyusho

                            Japan arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Paltusotine

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase III

                            Recipient : Crinetics Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Crinetics Pharmaceuticals and Sanwa Kagaku Kenkyusho Enter Into Exclusive Licensing Agreement for The Developm...

                            Details : Paltusotine is Crinetics’ investigational, orally available nonpeptide somatostatin receptor type 2 (SST2) agonist being evaluated as a treatment for acromegaly and neuroendocrine tumors (NETs), including NETs complicated by carcinoid syndrome.

                            Product Name : CRN00808

                            Product Type : Small molecule

                            Upfront Cash : $13.0 million

                            February 28, 2022

                            Lead Product(s) : Paltusotine

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Recipient : Crinetics Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sanwa Kagaku Kenkyusho

                            Japan arrow
                            ELCC
                            Not Confirmed

                            Sanwa Kagaku Kenkyusho

                            Japan arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Upacicalcet Sodium

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Sponsor : Kissei Pharmaceutical

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Launch of UPASITA® IV Injection Syringe for the Treatment of Secondary Hyperparathyroidism in Dialysis Patien...

                            Details : UPASITA® is administered by intravenous injection to dialysis patients through dialysis circuit and it is possible to adjust the dose and control the medication under the control of physicians or medical staffs.

                            Product Name : Upasita

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 19, 2021

                            Lead Product(s) : Upacicalcet Sodium

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Sponsor : Kissei Pharmaceutical

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth